Central Laboratory Capabilities
With laboratories in the US, Europe, China and Singapore, Medpace Labs has the global reach and capabilities to conduct NAFLD/NASH studies in concert with our full-service CRO or as a standalone service.
Biomarker Strategic Services
Medpace Labs’ test menu includes many validated biomarkers associated with NAFLD/NASH:
A2 Macroglobulin | C Peptide | Free Glycerol | NAS Calculation |
Adiponectin Total | Chylomicrons | Fructosamine | NMR |
Aldolase | CK18 M30 | G6PD | P1NP |
ANGPTL3 | CK18 M65 | Ghrelin | PIIINP |
ANGPTL4 | Cortisol Salivary | Glucose | Phosphatidylethanol |
Anti TPO | CRP, hs | GLP-1 Active | Pro BNP |
Apo A1 | CTX Beta Crosslaps | GLP-1 Total | Pro C3 |
Apo B | Cystatin C | Hyaluronic Acid | Proinsulin |
Apo B 48 | D Dimer | Haptoglobin | Pyruvic Acid |
Apo B 100 | ELF Panel | IL1 beta | Resistin |
Apo CII | Ferritin | IL6 | sLDL |
Apo CIII | FIB4 Calculation | Insulin | TGF Beta 1 |
APR Calculation | Fibrinogen | Lactate | TIMP-1 |
Autotaxin | Fibronectin | Leptin | TNF alpha |
Beta Hydroxybutyrate | Fibrotest | Lp(a) | Troponin I |
Bile Acids Fraction | FGF-19 | Lipid Panel | Vitamin D 25 OH |
Bile Acids Total | FGF-21 | MCP-1 | YKL-40 |
C4 (7-alpha) | Free Fatty Acids | NAFLD Calculation |
Our test menu also includes validated assays used in NASH fibrosis scores such as Fibrotest/FibroMax and ELF (Enhanced Liver Fibrosis).
Specialized Imaging for NAFLD/NASH Clinical Research
High-quality image acquisition and interpretation is crucial for the success of NAFLD/NASH trials. Medpace Core Labs provides comprehensive central imaging services including site assessment, qualification and training, advanced data processing and blinded assessments. In particular, Medpace Core Labs has expertise with the implementation of various MR-Based acquisition techniques including Magnetic Resonance Spectroscopy (MRS), Proton Density Fat Fraction (MRI-PDFF; magnitude and complex) and Magnetic Resonance Elastography (MRE) to support imaging endpoints for NAFLD/NASH trials using fully regulatory-compliant platforms.